Search results for "Agoni"

showing 10 items of 2493 documents

Comparison of ground reaction forces and antagonist muscle coactivation during stair walking with ageing

2006

Abstract Stair walking is a demanding task in old age. Ground reaction force (GRF) analysis, relative EMG activation, and muscular coactivation were performed during stair walking. The aim was to investigate the ageing effect on GRF distribution and muscle antagonist coactivation during stair walking, at varied speed. During ascending at maximal velocity old subjects demonstrated reduced GRF in all examined phases (range: 28–35%), whereas muscle coactivation only was elevated for the Entire stance phase (18.5%). GRF parameters during ascent and descent at freely chosen speed demonstrated differences between age groups (5–28%). Furthermore, muscle coactivation was elevated in old subjects (e…

AdultAgingmedicine.medical_specialtyAntagonist muscleStair walking Muscle coactivation Reserve capacity AgeingBiophysicsNeuroscience (miscellaneous)Stair walkingWalkingElectromyographyMuscle coactivationPhysical medicine and rehabilitationAge groupsmedicineHumansGround reaction forceMuscle SkeletalAgedmedicine.diagnostic_testElectromyographybusiness.industryCoactivationmedicine.anatomical_structureAgeingFemaleNeurology (clinical)businesshuman activitiesJournal of Electromyography and Kinesiology
researchProduct

Time-dependent changes in serum 3α-androstanediol glucuronide correlate with hirsutism scores after ovarian suppression

1995

The clinical utility of serum 3 alpha-androstanediol glucuronide level has been controversial. Among the concerns regarding its lack of utility has been the finding that suppression of serum 3 alpha-androstanediol glucuronide does not occur readily with treatment. We hypothesized that because the treatment of hirsutism requires a prolonged duration, a longer observation period is required for changes in serum 3 alpha-androstanediol glucuronide to be measured. Therefore, we studied the clinical and hormonal changes in 11 women treated for hirsutism with a gonadotropin-releasing hormone agonist (GnRH-a) for 1 year. A progressive reduction in Ferriman-Gallwey scores occurred, which was signifi…

AdultAgonistHirsutismmedicine.medical_specialtyAndrosterone glucuronidemedicine.drug_classEndocrinology Diabetes and MetabolismObservation period3-alpha-androstanediol glucuronideAndrosteroneEndocrinologyOvarian suppressionInternal medicinemedicineHumansTestosteronehirsutismTriptorelin Pamoatebusiness.industryObstetrics and Gynecologymedicine.diseaseAndrostane-317-diolEndocrinologyFemaleGlucuronidebusinessPolycystic Ovary SyndromeHormoneGynecological Endocrinology
researchProduct

Does Preoperative Treatment with a Gonadotropin-Releasing Hormone Agonist Improve the Outcome of Endometrial Resection?

1998

Abstract Study Objective. To verify if more favorable long-term results of endometrial resection can be obtained with preoperative gonadotropin-releasing hormone (GnRH) agonist treatment. Design. Multicenter, randomized, controlled trial (Canadian Task Force classification I). Setting. Tertiary care academic department. Patients. Sixty-three premenopausal women with established menorrhagia. Intervention. Eight weeks of goserelin depot treatment before endometrial resection or immediate surgery in the early proliferative phase of the cycle. Measurements and Main Results. Variations in menstrual patterns and bleeding scores as well as overall degree of satisfaction with treatment were determi…

AdultAgonistmedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classlaw.inventionEndometriumRandomized controlled triallawGonadotropin-releasing hormone agonistPreoperative CareFollicular phaseElectrocoagulationmedicineHumansProspective StudiesMenorrhagiabusiness.industryGoserelinObstetrics and GynecologyEndoscopyMiddle AgedSurgeryExact testTreatment OutcomeDelayed-Action PreparationsUterine NeoplasmsGoserelinFemaleAmenorrheamedicine.symptombusinessAdenomyomamedicine.drugHormone
researchProduct

β-Adrenoceptor stimulation up-regulates phosphodiesterase 4 activity and reduces prostaglandin E 2 -inhibitory effects in human neutrophils

2000

Human neutrophils were treated for 4 h with a combination of salbutamol (1 µM), a β2-adrenoceptor agonist, and rolipram (30 µM), a selective phosphodiesterase 4 inhibitor, to investigate whether this treatment produces up-regulation of phosphodiesterase activity with functional consequences. Anion-exchange chromatography coupled with the use of selective activators and inhibitors demonstrated that a phosphodiesterase activity with characteristics of the isoenzyme type 4 was increased in drug-treated cells. Kinetic analysis showed a ~1.5-fold increase in V max without alteration of K m values. The augmented phosphodiesterase activity in drug-treated cells was abolished by actinomycin D. Cycl…

AdultAgonistmedicine.medical_specialtyNeutrophilsmedicine.drug_classStimulationIn Vitro TechniquesBiologyDinoprostoneNeutrophil Activationchemistry.chemical_compoundPDE4BDownregulation and upregulationSuperoxidesInternal medicineCyclic AMPmedicineHumansAlbuterolRNA MessengerEnzyme InhibitorsProstaglandin E2RolipramPharmacologyReverse Transcriptase Polymerase Chain ReactionSuperoxideZymosanZymosanGeneral MedicineAdrenergic AgonistsCyclic Nucleotide Phosphodiesterases Type 4Up-RegulationEndocrinologychemistry3'5'-Cyclic-AMP PhosphodiesterasesReceptors Adrenergic beta-2Roliprammedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

δ 1‐OPIOID receptor‐mediated controlofacetylcholine (ACh) release in human neocortex slices

1998

In slices of human neocortex, prelabelled with [3H]-choline, the release of [3H]-acetylcholine reflects the evoked release of endogenous acetylcholine which was elicited by the same electrical stimulation paradigm. [3H]-Acetylcholine release was depressed by the delta-opioid receptor agonist D-Pen2-D-Pen5-enkephalin. When the nerve endings were depolarized by elevating extracellular potassium the evoked [3H]-acetylcholine release was similarly depressed by D-Pen2-D-Pen5-enkephalin in the absence, but not in the presence, of tetrodotoxin which blocks action potential propagation. Therefore, the delta-opioid receptor inhibiting [3H]-acetylcholine release should not be located to cholinergic n…

AdultAgonistmedicine.medical_specialtymedicine.drug_classNarcotic AntagonistsNeocortexTetrodotoxinIn Vitro TechniquesOctreotideBenzylidene Compoundschemistry.chemical_compoundDevelopmental NeuroscienceInterneuronsOpioid receptorReceptors Opioid deltaInternal medicinemedicineHumansReceptorAgedAged 80 and overNeocortexEnkephalinsMiddle AgedReceptor antagonistAcetylcholineElectric StimulationNaltrexoneEndocrinologymedicine.anatomical_structurenervous systemchemistryTetrodotoxinCholinergicEnkephalin D-Penicillamine (25)-AcetylcholineDevelopmental Biologymedicine.drugInternational Journal of Developmental Neuroscience
researchProduct

Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry

2023

The European Society of Cardiology (ESC) EURObservational Research Programme (EORP) Non-ST-segment elevation myocardial infarction (NSTEMI) Registry aims to identify international patterns in NSTEMI management in clinical practice and outcomes against the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without ST-segment-elevation. Consecutively hospitalised adult NSTEMI patients (n = 3620) were enrolled between 11 March 2019 and 6 March 2021, and individual patient data prospectively collected at 287 centres in 59 participating countries during a two-week enrolment period per centre. The registry collected data relating to baseline characteristics,…

AdultAngiotensin Receptor AntagonistsAspirinHealth PolicyHumansAngiotensin-Converting Enzyme InhibitorsHospital MortalityRegistries03.02. Klinikai orvostanNon-ST Elevated Myocardial InfarctionCardiology and Cardiovascular Medicine
researchProduct

Nonlinear coupling is absent in acute myocardial patients but not healthy subjects.

2008

We investigated whether autonomic nervous system imbalance imposed by pharmacological blockades and associated with acute myocardial infarction (AMI) is manifested as modifications of the nonlinear interactions in heart rate variability signal using a statistically based bispectrum method. The statistically based bispectrum method is an ideal approach for identifying nonlinear couplings in a system and overcomes the previous limitation of determining in an ad hoc way the presence of such interactions. Using the improved bispectrum method, we found significant nonlinear interactions in healthy young subjects, which were abolished by the administration of atropine but were still present afte…

AdultAtropineMaleSympathetic Nervous SystemPhysiologyAdrenergic beta-AntagonistsModels NeurologicalMyocardial InfarctionMuscarinic AntagonistsElectrocardiographyHeart RateParasympathetic Nervous SystemPhysiology (medical)medicineAutonomic nervous systemHumansMyocardial infarctionNonlinear couplingHeart rate variabilityAgedBispectrumModels Statisticalbusiness.industryHealthy subjectsAge FactorsModels CardiovascularReproducibility of ResultsHeartMiddle Agedmedicine.diseasePropranololAutonomic nervous systemNonlinear DynamicsAnesthesiaCase-Control StudiesSettore ING-INF/06 - Bioingegneria Elettronica E InformaticaFemalebusinessCardiology and Cardiovascular MedicineAlgorithmsAmerican journal of physiology. Heart and circulatory physiology
researchProduct

Effect of histamine and histamine analogues on human isolated myometrial strips.

1992

1. The effect of histamine and histamine H1- and H2-receptor agonists on isolated myometrium strips of premenopausal women has been examined. The effect of acetylcholine was also determined. 2. Histamine, 2-pyridylethylamine, 4-methylhistamine and acetylcholine, but not dimaprit, produced a concentration-related contractile response in human isolated myometrial strips. Histamine also produced a further contraction in human isolated myometrial strips precontracted with KCl (55 mM). 3. The contractile response to histamine was antagonized by the histamine H1-receptor antagonist, clemizole (0.1 microM) but was potentiated by the histamine H2-receptor antagonist, ranitidine (10 microM). Clemizo…

AdultAtropinemedicine.medical_specialtyPyridinesMuscle RelaxationHistamine H1 receptorRanitidineHistamine agonistPotassium ChlorideHistamine Agonistschemistry.chemical_compoundHistamine receptorUterine ContractionHistamine H2 receptorInternal medicinemedicineHumansPharmacologyDose-Response Relationship DrugMethylhistaminesMuscle SmoothMiddle AgedDimapritAcetylcholineClemizoleEndocrinologyMuscle relaxationchemistryMyometriumBenzimidazolesFemaleHistamineHistamineResearch ArticleBritish journal of pharmacology
researchProduct

Subcutaneous and omental fat expression of adiponectin and leptin in women with polycystic ovary syndrome

2007

Objective To assess message expression of adiponectin and leptin in visceral and SC fat in women with polycystic ovary syndrome (PCOS) and in control women. Design Prospective clinical trial. Setting Academic medical centers in Mexico City, Mexico and New York, New York. Patient(s) Women with PCOS and control women. Intervention(s) Surgical biopsies of visceral (omental) and subcutaneous (SC) adipose tissue, fasting blood samples, and ultrasound measurements of visceral and SC fat. Main Outcome Measure(s) Messenger RNA assessment of adiponectin and leptin in adipose tissue samples; serum measurements of adiponectin, leptin, glucose, insulin, and hormone levels; measurements of fat quantity …

AdultBlood GlucoseLeptinmedicine.medical_specialtymedicine.medical_treatmentAbdominal FatNew YorkSubcutaneous FatAdipokineAdipose tissueBody Mass IndexSettore MED/13 - EndocrinologiaInsulin resistanceInternal medicineAbdominal fat adiponectin leptin polycystic ovary syndrome insulin resistancemedicineHumansInsulinProspective StudiesRNA MessengerMexicoUltrasonographyAdiponectinbusiness.industryLeptinInsulinnutritional and metabolic diseasesObstetrics and Gynecologymedicine.diseasePolycystic ovaryEndocrinologyReproductive MedicineCase-Control StudiesFemaleAdiponectinInsulin ResistancebusinessBody mass indexhormones hormone substitutes and hormone antagonistsPolycystic Ovary Syndrome
researchProduct

Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study

2020

Objective To explore the glucagon-like peptide-1 analogue liraglutide in the hospital setting in patients with type 2 diabetes mellitus (T2DM) and acute coronary syndrome and to evaluate the safety and efficacy and its impact on hospitalization and short-term glycemic variability (GV). Methods A 12-week, open-label, prospective, randomized pilot clinical study with parallel groups that compared liraglutide (group 1) with glargine (group 2) and its impact on glycemic control and GV. Results Thirteen patients were included. During hospitalization, mean glucose was 164.75 mg/dL (standard deviation [SD] 19.94) in group 1 and 166.69 mg/dL (38.22) in group 2. GV determined by CV and SD was 20.98 …

AdultBlood GlucoseMaleAcute coronary syndromemedicine.medical_specialtyProspective Clinical Research ReportMedicine (General)Hospital settingtype 2 diabetes mellitusGLP-1 receptor agonistInsulin Glargine030209 endocrinology & metabolismPilot Projects030204 cardiovascular system & hematologyHypoglycemiaBiochemistryacute coronary syndrome03 medical and health sciencesRandom Allocation0302 clinical medicineR5-920Internal medicineMedicineHumansHypoglycemic AgentsInsulinGlycemic variabilityGlucagon-like peptide 1 receptorGlycemicGlycated Hemoglobinliraglutidebusiness.industryInsulin glargineLiraglutideBiochemistry (medical)Type 2 Diabetes MellitusCell BiologyGeneral MedicineMiddle Agedmedicine.diseaseHypoglycemiaMetforminDiabetes Mellitus Type 2Glycemic IndexSpainFemalebusinessmedicine.drugJournal of International Medical Research
researchProduct